Digene wins HPV (human papillomavirus) deal extension with Quest:
This article was originally published in Clinica
Gaithersburg, Maryland-based molecular diagnostics company Digene is to supply diagnostic testing service provider Quest Diagnostics with products related to human papillomavirus (HPV) testing for an additional four years. The new agreement, an extension to an existing three-year supply deal, will see Lyndhurst, New Jersey-based Quest running Digene's HPV test, said to be the only FDA-approved test for high-risk types of the cervical cancer-related virus, on the latter's Rapid Capture automated, high-thoroughput analyser.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.